Efficacy of Xueshuantong Injection in Reducing Residual Inflammatory Risk in Unstable Angina Patients: A Randomized Double-Blind Controlled Trial

WANG Ya-xing; LYU Jian; LU Zhen-kai; LIU Mi; FENG Wen-ye; XIE Yan-ming; LIU Guang-yu

doi:10.1007/s11655-025-4023-6

Your Location：

Home >

Browse articles >

Efficacy of Xueshuantong Injection in Reducing Residual Inflammatory Risk in Unstable Angina Patients: A Randomized Double-Blind Controlled Trial

Clinical Experience | Updated：2026-02-14

- Efficacy of Xueshuantong Injection in Reducing Residual Inflammatory Risk in Unstable Angina Patients: A Randomized Double-Blind Controlled Trial
- Chinese Journal of Integrative Medicine Vol. 32, Issue 1, Pages: 73-79(2026)
- Affiliations：
  
  1.Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100700), China
  2.Institute of Clinical Basic Medicine of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing (100700), China
  3.Operations Management Department, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing (100700), China
- Author bio：
  
  Prof. LIU Guang-yu, E-mail: liuguangyu78@126.com
- Funds：
- DOI：10.1007/s11655-025-4023-6
  CLC：
- Accepted：11 July 2025，
  
  Online First：20 October 2025，
  
  Published：2026-01
- Accepted：
Scan QR Code
WANG Ya-xing, LYU Jian, LU Zhen-kai, et al. Efficacy of Xueshuantong Injection in Reducing Residual Inflammatory Risk in Unstable Angina Patients: A Randomized Double-Blind Controlled Trial[J]. Chinese Journal of Integrative Medicine, 2026, 32(1): 73-79.
DOI：

WANG Ya-xing, LYU Jian, LU Zhen-kai, et al. Efficacy of Xueshuantong Injection in Reducing Residual Inflammatory Risk in Unstable Angina Patients: A Randomized Double-Blind Controlled Trial[J]. Chinese Journal of Integrative Medicine, 2026, 32(1): 73-79. DOI： 10.1007/s11655-025-4023-6.

摘要

Abstract

Objective:

To evaluate the clinical efficacy and safety of Xueshuantong Injection (Lyophilized)(XST) in reducing residual inflammatory risk (RIR) in patients with unstable angina (UA).

Methods:

This was a randomized

double-blind

parallel-controlled multicenter trial. Patients with UA were recruited from Xiyuan Hospital and Guang'anmen Hospital of the China Academy of Chinese Medical Sciences between January 2024 and March 2025. Eligible participants were randomly assigned to the treatment group (XST 500 mg

30 cases) or the control group (XST 25 mg

30 cases) in a 1:1 ratio. Both groups received intravenous XST for 10 consecutive days along with standard medical therapy. The primary outcome was change in C-reactive protein(CRP) level from baseline to post-treatment. Secondary outcomes included changes in interleukin-6 (IL-6)

matrix metalloproteinase-9 (MMP-9)

high-mobility group box 1 (HMGB1)

vascular endothelial growth factor(VEGF)

and von Willebrand factor (vWF)

as well as the Canadian Cardiovascular Society (CCS) classification

and Chinese Medicine (CM) syndrome scores. Safety was evaluated by monitoring adverse event (AE) and performing laboratory tests of liver and kidney function before and after treatment.

Results:

A total of 59 patients completed the trial (30 in the treatment group and 29 in the control group). After treatment

the treatment group showed significantly greater reductions in CRP levels compared to the control group (

0.01). In addition

the treatment group exhibited significantly improved IL-6

MMP-9

and HMGB1 levels

as well as CM symptom scores and CCS classification compared to the control group (all

0.05). No serious adverse events were reported. Compared with the control group

the treatment group receiving XST showed greater improvements in RIR and clinical symptoms in UA patients with good safety and tolerability.

Conclusion:

XST shows potential to reduce RIR in patients with UA and may inform anti-inflammatory management. (Registration No. ITMCTR2025000552)

关键词

Keywords

references

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention:A Multicenter, Open-Labeled, Randomized Controlled Trial^*

Effectiveness and Safety of Auricular Acupressure Combined with Periocular Thumbtack Needle Therapy for Premyopic Children: A Multicenter, Randomized, Controlled Trial

Efficacy and Safety of Aurantii Fructus Immaturus Flavonoid Tablets in Patients with Functional Dyspepsia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Trial

Efficacy and Safety of Qiming Granule for Nerve Injury Associated with Non-proliferative Diabetic Retinopathy: A Multicenter, Randomized, Non-inferiority, Active-Controlled Clinical Trial

Lu'e Biyan Formula for Treatment of Allergic Rhinitis Patients with Fei (Lung)-Qi Deficiency-Coldness Syndrome: A Randomized, Double Blind, and Placebo-Controlled Trial^*

Related Author

Xiao-juan MA

Wen-hui DUAN

Ying ZHANG

Jie GAO

Bao-yi GUAN

Ke-ji CHEN

Da-zhuo SHI

HOU Xin-yue

Related Institution

National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Ophthalmology, Eye Hospital, China Academy of Chinese Medical Sciences

Department of Ophthalmology, Beijing Hospital of Traditional Chinese Medicine

Department of Ophthalmology, Shenzhen Traditional Chinese Medicine Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰